Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:38:07.369Z.
Calculation as of: 2026-10-06T20:38:07.369Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 033b533528001a3499036996a5838431eca9b2abd512acbebbb4929ff412c5bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$777.34M
PS Ratio
18.75
TTM Avg
12.05
3Y Avg
176.43
5Y Avg
968.45
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $765.30M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.37M | 3.05 | 2.14 | 2.44 | 3.85 |
| Geron Corporation (GERN)vs › | $776.24M | 3.79 | 4.98 | 1623.75 | 1489.80 |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $777.34M | 18.75 | 12.05 | 176.43 | 968.45 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.02M | N/A | N/A | N/A | N/A |
| Varex Imaging Corporation (VREX)vs › | $778.01M | 0.90 | 0.63 | 0.69 | 0.86 |
| Design Therapeutics, Inc. (DSGN)vs › | $747.61M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | 0.26 | 0.48 | 0.44 | 0.69 |
| Apnimed, Inc. (APMD)vs › | $742.70M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $789.34M | 6.61 | 6.23 | 9.08 | 36.05 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
